References
- Smith D. C., Prentice R., Thompson D. J., Herrmann W. L. Association of exogenous oestrogen and endometrial carcinoma. N. Engl. J. Med. 1975; 293: 1164–7
- Ziel H. K., Finkle W. D. Increased risk of endometrial carcinoma among users of conjugated oestrogens. N. Engl. J. Med. 1975; 293: 1167–70
- Gambrcll R. D., Jr, Massey F. M., Castaneda I. A., Ugenas A. J., Ricci C. A., Wright J. M. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obitct. Gynecol 1980; 55: 732–8
- Gambrell R. D., Jr, Bagnell C. A., Greenblatt R. D. Role of oestrogens and progesterone in the aetiology and prevention of endometrial cancer: review. Am. J. Obstet. Gynecol. 1983; 146: 696–707
- Whitehead M. I., Siddle N. C., Townscnd P. T., Lane G., King R. J.B. The use of progestins and progesterone in the treatment of climacteric and postmenopausal symptoms. Progesterone and Progestins, C. W. Bar-din, E. Milgrom, P. Mauvais-Jarvis. Raven Press, New York 1983; 277–94
- Lind T., Cameron E. C., Hunter W. M., Leon C., Moran P. F., Oxley A., Gerrard J., Lind U. C. A prospective, controlled trial of six forms of hormone replacement therapy given to postmenopausal women. Br.J. Obstet. Gynaecol. 1979; 86(Suppl. 3)1–29
- Magos A. L., Brincat M L, Studd J. W. W., Wardle P., Schlesinger P., O'Dowd T. Amenorrhoea and endometrial atrophy with continuous oral oestrogen and progestogen therapy in postmenopausal women. Obstet. Gynecol. 1985; 65: 496–9
- Magos A. L., Brewster E., Singh R., O'Dowd T., Brincat M., Studd J. W. W. The effects of norethisterone in postmenopausal women on hormone replacement therapy: a model for the premenstrual syndrome. Br.J. Obstet. Gynaecol. 1986; 93: 1290–6
- Whitehead M. I., Townsend P. T., Gill D. K., Collins W. P., Campbell S. Absorption and metabolism of oral progesterone. Br. Med. J. 1980; 280: 825–7
- Maxson W. S., Hargrove J. T. Bioavailability of oral micronised progesterone. Fertil. SteriL 1985; 44: 622–6
- Bolaji I. I., Tallon D., O'Dwyer E. M., Fot-trcll P. F. Assessment of bioavailability of micronised oral progesterone using a salivary progesterone enzymeimmunoassay. Gynecol. Endocrinol. 1993; 7: 101–10
- Helsinki Declaration. 1989, Helsinki Declaration adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964, and as revised by the 41st World Medical Assembly, Hong Kong, May
- Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972; 18: 499–502
- Hargrove J. T., Maxson W. S., Wentz A. C. Absorption of oral progesterone is influenced by vehicle and particle size. Am. J. Obstet. Gynecol. 1989; 161: 948–51
- Whitehead M. I., Hillard T. C., Crook D. The role and use of progestogens. Obstet. Gynecol. 1990; 75: 59S–76S
- Bolaji I. I., O'Dwyer E. M. Postmenopausal cyclic eruptions: autoimmune progesterone dermatitis. Eur. J. Obstet. Gynecol. Reprod. Biol. 1992; 47: 169–71
- Punnonen R., Liukko P., Cortes-Preko J., Eydam F., Milojevic S., Trevoux R., Chrys-sikopoulos E., Franchi F., Luisi M., Kicovic P. M. Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in postmenopausal and oo-phorectomised women. Maturitas 1984; 5: 281–6